Replimune Group Inc
(FRA:7R8)
€
9.22
-0.34 (-3.56%)
Market Cap: 810.48 Mil
Enterprise Value: 672.35 Mil
PE Ratio: 0
PB Ratio: 5.33
GF Score: 32/100 Replimune Group Inc at JPMorgan Healthcare Conference Transcript
Jan 14, 2026 / 09:30PM GMT
Release Date Price:
€6.6
(-7.69%)
Anupam Rama
JPMorgan Chase & Co - Analyst
All right. Let's go ahead and get started. Welcome, everyone, to the 44th Annual JPMorgan Healthcare Conference. My name is Anupama Rama. I am one of the senior biotech analysts here at JPMorgan. I'm joined by my squad, Joyce Zhou, Priyanka Grover, and Rathi Pinhe. Our next presenting company is Replimune, and presenting on behalf of the company, we have CEO, Sushil Patel.
Sushil Patel
Replimune Group Inc - Chief Executive Officer, Director
Thank you, Anupam. I just refer you to our -- it's working?
Anupam Rama
JPMorgan Chase & Co - Analyst
Sushil if the slides don't work, do you want to just make this the fire side where you and I can just have a chat?
Sushil Patel
Replimune Group Inc - Chief Executive Officer, Director
Happy to do that. Safe Harbor statement. I'm playing catch up now. All right. I'll refer you to our forward-looking statements.
So it's been a -- 2025 was a tumultuous year for Replimune,
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot